The Effect Of The Oral Iron Chelator Deferiprone On The Liver Damage Induced By Tamoxifen In Female Rats
- 20 May 2011
- journal article
- Published by Taylor & Francis in Hemoglobin
- Vol. 35 (3), 255-261
- https://doi.org/10.3109/03630269.2011.560780
Abstract
Tamoxifen (TAM) is a non-steroidal antiestrogen used in the treatment and prevention of hormone-dependent breast cancer. Tamoxifen therapy may be accompanied with hepatic injury and iron accumulation in this organ. The present study investigates the influence of the effective oral iron chelator, deferiprone (L1), in TAM-induced acute liver injury. Four groups of female Wistar rats were used: I, control; II, TAM; III, TAM+L1; IV, L1. Tamoxifen (75 mg/kg) was administered orally on the first and second day; L1 (50 mg/kg) was administered orally on the first, second and third day of the experiment. On the fourth day, parameters of oxidative state: lipid peroxidation (LP), glutathione (GSH) and catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GPx) activities were estimated in liver homogenates. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamate dehydrogenase (GLDH) levels and iron hepatic content were also evaluated. The TAM-induced oxidative damage was demonstrated by increased LP (52% above controls) and decreased GPx activity (to 92% of controls). The protective effect of L1 was manifested by attenuation of LP (p <0.05) and preserving of GPx activity. The TAM-induced increase of serum ALT and AST activity remained unchanged by L1 treatment. Significant increase of hepatic iron (Fe) level (41% above controls) was found in TAM-treated rats. Hepatic Fe accumulation was completely prevented by L1 treatment.Keywords
This publication has 19 references indexed in Scilit:
- Liver iron overload induced by tamoxifen in diabetic and non-diabetic female Wistar ratsBioMetals, 2007
- THE ROLE OF METABOLIC ACTIVATION IN DRUG-INDUCED HEPATOTOXICITYAnnual Review of Pharmacology and Toxicology, 2005
- The Design and Development of Deferiprone (L1) and Other Iron Chelators for Clinical Use: Targeting Methods and Application ProspectsCurrent Medicinal Chemistry, 2004
- Hepatitis tóxica asociada al uso de tamoxifeno.Presentación de un caso y revisión bibliográficaGastroenterología y Hepatología, 2002
- Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1)Transfusion Science, 2000
- Tamoxifen in the Treatment of Breast CancerNew England Journal of Medicine, 1998
- Tamoxifen in liver disease: Potential exacerbation of hepatic dysfunctionAnnals of Oncology, 1998
- Tamoxifen: Toxicities and Drug Resistance During the Treatment and Prevention of Breast CancerAnnual Review of Pharmacology and Toxicology, 1995
- TamoxifenDrugs, 1989
- Hepatic Mitochondrial Oxidative Metabolism in Rats With Chronic Dietary Iron OverloadHepatology, 1985